[{"orgOrder":0,"company":"Butantan Institute","sponsor":"Sinovac Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine (Inactivated, Adsorbed)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Butantan Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Butantan Institute \/ Sinovac Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Butantan Institute \/ Sinovac Biotech"},{"orgOrder":0,"company":"Butantan Institute","sponsor":"Butantan Institute","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BRAZIL","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Dengue 1,2,3,4 (attenuated) Vaccine","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Butantan Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Butantan Institute \/ Butantan Institute","highestDevelopmentStatusID":"10","companyTruncated":"Butantan Institute \/ Butantan Institute"},{"orgOrder":0,"company":"Butantan Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Butantan Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Butantan Institute \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Butantan Institute \/ Undisclosed"},{"orgOrder":0,"company":"Butantan Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"V181","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Butantan Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Butantan Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Butantan Institute \/ Merck & Co"},{"orgOrder":0,"company":"Butantan Institute","sponsor":"Valneva","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"VLA1553","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Butantan Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Butantan Institute \/ Valneva","highestDevelopmentStatusID":"10","companyTruncated":"Butantan Institute \/ Valneva"}]